A Phase 1b/2 Study to Assess the Safety and Efficacy of AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 04 Jun 2015
At a glance
- Drugs Rilotumumab (Primary) ; Mitoxantrone; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Sponsors Amgen
- 10 Jun 2017 Biomarkers information updated
- 04 Feb 2012 Results presented at the 2012 Genitourinary Cancers Symposium.
- 08 Sep 2011 Planned end date changed from 1 Mar 2013 to 1 Sep 2012 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History